Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ascendis Pharma A/s.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.816 Ladies and gentlemen, thank you for standing by and welcome to Ascendus Pharma first 00:00:04.816 -- 00:00:10.381 quarter 2025 earnings conference call. At this time, all participants are in the listen-only 00:00:10.381 -- 00:00:15.846 mode. After the speaker's presentation, there will be a question and answer session. 00:00:15.846 -- 00:00:20.570 To ask a question during the session, you will need to press star 11 on your telephone. 00:00:20.570 -- 00:00:24.614 You will then hear an automated message advising your hand is raised. 00:00:24.614 -- 00:00:28.077 To withdraw your question, please press star 11 again. 00:00:28.077 -- 00:00:31.701 Please be advised that today's conference is being recorded. 00:00:31.701 -- 00:00:36.305 I would like now to turn the conference over to Scott Smith, Vice President and Chief 00:00:36.305 -- 00:00:40.290 Financial Officer. Please go ahead, sir. 00:00:40.290 -- 00:00:45.895 Thank you so much, operator. And thank you, everyone, for joining our first quarter 2025 00:00:45.895 -- 00:00:50.901 Financial Results Conference Call. I'm Scott Smith, Chief Financial Officer at 00:00:50.901 -- 00:00:55.906 Ascendus Pharma. Joining me on the call today are Yen Mickelson, President and 00:00:55.906 -- 00:01:01.284 Chief Executive Officer, Sherry Glass, Chief Business Officer, Jay Wu, 00:01:01.284 -- 00:01:06.312 Executive Vice President and President Ascendus US, and Amy Hsu, Chief Medical 00:01:06.312 -- 00:01:07.894 Officer. 00:01:07.894 -- 00:01:11.600 Before we begin, I'd like to remind you that this conference call will contain forward-looking 00:01:11.600 -- 00:01:15.305 statements that are intended to be covered under the safe harbor provided by the Private 00:01:15.305 -- 00:01:20.006 Securities Lit...